Protocols for Solid Tumors
| HIC 0701002180 Gary Kupfer Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor |
| HIC 0604001305 Wm. Kevin Kelly M.D. Open Label, Dose Escalation Trial of Oral PXD101 in patients with Advanced Solid Tumors |
| HIC 0807004099 Mario Sznol M.D. A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of MDX-1106 in Subjects with Selected Advanced or Recurrent Malignancies |
| HIC 0511000860 Maysa Abu-Khalaf M.D. A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination with Abraxane (Paclitaxel protein-bound particles) in Advanced Solid Cancers |
| HIC 0705002670 Wasif Saif M.D. A Phase I, Open-Label, Non-Randomized, Dose-Finding, Safety, Tolerance, and Pharmacokinetic Study of Orally Administered S-1 in Combination with Gemcitabine in Patients with Advanced Solid Tumors |
| HIC 0906005239 Madhav Dhodapkar M.D. A Phase I/II Open-Label, Dose-Escalation Study of CDX-1401 in Patients with Malignancies Expressing NY-ESO-1 |
| HIC 0811004508 Maysa Abu-Khalaf M.D. A Phase IB, Open-label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors |
| HIC 0808004167 Wasif Saif M.D. A Phase IB/II Multi-Center Clinical Study of PHY906 as a Modulator of CPT-11 Chemotherapy in Patients with Metastatic Colorectal Cancer |
| HIC 0811004438 Wasif Saif M.D. A Phase I Investigation of MK-5108 and MK-5108 With Docetaxel in Patients With Patients with Advanced Solid Tumors |